ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 2122

Plasma chemerin as a Useful Marker for Disease Activity in Patients with Rheumatoid Arthritis

Sang Tae Choi1, You-Jung HA2, Eun-Jin Kang3, Kwang-Hoon Lee4 and Jung-Soo Song1, 1Rheumatology, Chung-Ang University College of Medicine, Seoul, South Korea, 2Division of Rheumatology, Department of Internal Medicine, Kwanding University College of Medicine, Myongji Hospital, Goyang, South Korea, 3Rheumatology, Busan Medical Center, Busan, South Korea, 4Dongguk University Ilsan Hospital, Goyang, South Korea

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords:

Session Information

Title: Rheumatoid Arthritis - Clinical Aspects III: Infections/Risk Factors for Incident Rheumatoid Arthritis/Metrology/Classification/Biomarkers/Predictors of Rheumatolid Arthritis Activity & Severity

Session Type: Abstract Submissions (ACR)

Background/Purpose: Chemerin is an adipokine that is linked to adipogenesis and chemotaxis of the innate immune system. It is expressed on macrophage, dendritic cells, and synovial lining and sublining cells. It has been reported that chemerin has both pro-inflammatory and anti-inflammatory roles, and higher level of chemerin was detected in various chronic inflammatory diseases. Recent studies have showed that its expression is increased in the synovium of patients with rheumatoid arthritis (RA), and the chemerin may play an important role in the pathogenesis of RA. However, the association between plasma chemerin level and disease activity in RA patients remains unclear. This study aims to determine whether plasma chemerin level is elevated in patient with RA and its correlation with disease activity and other parameters.

Methods: This study includes 71 RA patients and 42 age- and sex- matched healthy controls. Plasma samples were obtained from healthy controls and patients with RA during active and inactive disease status. We assessed the clinical characteristics and laboratory parameters including body mass index (BMI), erythrocyte sedimentation rate, C-reactive protein, and disease activity score 28 (DAS28). The plasma level of chemerin and tumor necrosis factor (TNF)-α were determined using enzyme-linked immunosorbent assay (ELISA).

Results: Plasma chemerin level was significantly elevated in patients with RA than healthy control (9.074 ± 13.513 pg/mL vs 0.370 ± 0.219 pg/mL, p<0.001). In RA patients, the adjusted plasma chemerin level according to BMI was correlated with DAS28 (γ=0.340, p=0.004), but not plasma TNF- α level. The adjusted plasma chemerin level of active disease group patients (DAS28 ≥ 2.6) was significantly higher than that of remission group patients (DAS28 < 2.6) (0.591 ± 0.879 pg/mL vs 0.220 ± 0.154 pg/mL, p = 0.015).

Conclusion: Patients with RA showed higher plasma chemerin than that of healthy controls. The adjusted plasma chemerin level according to BMI was well correlated with RA disease activity. These findings suggest that plasma chemerin could play a role in the inflammatory process of RA, and that it may be a useful disease activity marker in RA.

Disclosure:

S. T. Choi,
None;

Y. J. HA,
None;

E. J. Kang,
None;

K. H. Lee,
None;

J. S. Song,
None.

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/plasma-chemerin-as-a-useful-marker-for-disease-activity-in-patients-with-rheumatoid-arthritis/